1397-0012
AirleafTM Bronchiectasis Study
Study Title
A randomised, double-blind, placebo-controlled, parallel group, dose-finding study evaluating efficacy, safety and tolerability of BI 1291583 qd over at least 24 weeks in patients with bronchiectasis (AirleafTM)
Study duration
Up to 12 months
Number of CLINIC VISITS
Up to 10
NUMBER OF PHONE CALLS
Up to 5
Main entry criteria
- 18 to 85 years of age
- Confirmed diagnosis of bronchiectasis
- Has had at least 1 bronchiectasis exacerbation requiring antibiotic treatment in the past 12 months
There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.
Assessments
- Breathing tests
- Blood pressure and pulse
- Questionnaires
- ECGs
- Blood and urine tests
- Sputum samples
- Dental check-ups
You will receive all study-related procedures, medications, and laboratory services at no cost. In addition, you will be reimbursed $70 per visit for your time and travel.